New Delhi, Sep 17 (PTI) Dr Reddy's Laboratories on Thursday said it has launched an over-the-counter (OTC) eye allergy drop Olopatadine Hydrochloride Ophthalmic Solution in the US market.

The newly-launched product is the storebrand equivalent of Novartis AG's Pataday, the drug major said in a regulatory filing.

Also Read | Facebook Smart Glasses in Collaboration With RayBan, Armani, Oakley & Versace Eyewear Maker to Be Launched in 2021.

Dr Reddy's said Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 per cent and 0.1 per cent, are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent, is also indicated for the temporary relief of red eyes.

Also Read | Mi Smart Band 5 Launching in India on September 29; Expected Prices, Features & Specifications.

This launch marks the entry of Dr Reddy's into the OTC eye care space, and is a testament to our deep capabilities in bringing store-brand equivalents of prescription to OTC switches to the US market, Marc Kikuchi, CEO, North America Generics, Dr Reddy's Laboratories said.

Quoting IRi data, Dr Reddy's said the Pataday brand had US sales of approximately USD 31 million since the launch in March 2020.

Shares of Dr Reddy's Laboratories were trading 2.47 per cent higher at Rs 4,746 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)